Search

Your search keyword '"D'AMORE, Fabio"' showing total 28 results
Start Over Author "D'AMORE, Fabio"
28 results on '"D'AMORE, Fabio"'

2. Efficacy of 1 L polyethylene glycol plus ascorbate versus 4 L polyethylene glycol in split-dose for colonoscopy cleansing in out and inpatient: A multicentre, randomized trial (OVER 2019)

Author

Vassallo, Roberto, Maida, Marcello, Zullo, Angelo, Venezia, Ludovica, Montalbano, Luigi, Mitri, Roberto Di, Peralta, Marco, Virgilio, Clara, Pallio, Socrate, Pluchino, Dario, D'amore, Fabio, Santagati, Alessio, Sinagra, Emanuele, Graceffa, Pietro, Nicosia, Giuseppe, Camilleri, Salvatore, Gibiliaro, Gerlando, Abdelhadi, Yasmin, Rancatore, Gabriele, Scalisi, Giuseppe, Melita, Giuseppinella, Magnano, Antonio, Conoscenti, Giuseppe, and Facciorusso, Antonio

Published
2024
Full Text
View/download PDF

3. Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study.

Author

Zoletto, Simone, Pizzi, Marco, De Crescenzo, Andrea, Friziero, Alberto, D'Amore, Fabio, Carli, Giuseppe, Vianelli, Nicola, Auteri, Giuseppe, Bertozzi, Irene, Nichele, Ilaria, Binotto, Gianni, Dei Tos, Angelo Paolo, Scarmozzino, Federico, D'Amore, Emanuele S. G., Ceccato, Jessica, Sabattini, Elena, Cinetto, Francesco, Piazza, Francesco, Visentin, Andrea, and Zambello, Renato

Subjects
IDIOPATHIC thrombocytopenic purpura, DISEASE relapse, PROGNOSIS, MEDICAL personnel, IMMUNE response, SPLENECTOMY
Abstract

Background/Objectives: Splenectomy leads to a high rate of remission in chronic primary immune thrombocytopenia (ITP), but its unpredictable long-term positive outcomes and that it is a irreversible surgical approach discourage clinicians and patients. The identification of predictors of response may redefine the timing of splenectomy. In this retrospective, multicentric study we aimed to investigate clinical–histological predictors of splenectomy response in ITP patients and provide an easy-to-use score to predict splenectomy response in ITP. Methods: We considered a discovery set (n = 17) and a validation set (n = 30) of adult ITP patients, who underwent splenectomy for refractory disease in three Italian referral centers for ITP. Results: We found that the presence of autoimmune comorbidities, daily steroid dose prior to splenectomy, age at diagnosis and age at splenectomy were significantly associated with the outcome. Variables singly associated with an adverse outcome were combined into a clinical and a clinical–pathological score, allowing us to define a "high-risk" group which accounted for about 80% of the disease relapses observed in this cohort. At the same time, a certain clinical–pathological score indicated a "high-risk" group characterized by significantly poorer outcomes. Results were confirmed in the validation cohort. Conclusions: An integrated set of clinical and histological parameters may predict the response to splenectomy in ITP patients. While these findings provide valuable insights, they were derived from a small cohort of patients and therefore require validation in larger, more diverse populations to ensure their generalizability and robustness. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

4. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy

Author

Bonifacio, Massimiliano, Scaffidi, Luigi, Binotto, Gianni, Miggiano, Maria Cristina, Danini, Marco, Minotto, Claudia, Griguolo, Davide, Marin, Luciana, Frison, Luca, D’Amore, Fabio, Basso, Marco, Sartori, Roberto, Tinelli, Martina, Stulle, Manuela, Fortuna, Stefania, Bonalumi, Angela, Bertoldero, Giovanni, De Biasi, Ercole, Ruggeri, Marco, Semenzato, Gianpietro, Fanin, Renato, Pizzolo, Giovanni, Krampera, Mauro, and Tiribelli, Mario

Published
2018
Full Text
View/download PDF

6. P1601: PREDICTING THE RESPONSE TO SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA (ITP): A MULTI-CENTRIC PILOT STUDY

Author

Zoletto, Simone, primary, Pizzi, Marco, additional, Andrea, De Crescenzo, additional, D’amore, Fabio, additional, Friziero, Alberto, additional, Bertozzi, Irene, additional, Carli, Giuseppe, additional, Famengo, Barbara, additional, Nichele, Ilaria, additional, Vianelli, Nicola, additional, Auteri, Giuseppe, additional, Sabattini, Elena, additional, Tos, Angelo Paolo Dei, additional, Trentin, Livio, additional, and Vianello, Fabrizio, additional

Published
2023
Full Text
View/download PDF

7. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies

Author

Angotzi, Francesco, primary, Petrella, Marco, additional, Berno, Tamara, additional, Binotto, Gianni, additional, Bonetto, Giorgia, additional, Branca, Antonio, additional, Carraro, Marco, additional, Cavaretta, Chiara Adele, additional, Cellini, Alessandro, additional, D’Amore, Fabio, additional, Forlani, Laura, additional, Gianesello, Ilaria, additional, Gurrieri, Carmela, additional, Imbergamo, Silvia, additional, Lessi, Federica, additional, Maroccia, Antonio, additional, Mazzetto, Federica, additional, Pavan, Laura, additional, Pezone, Sara, additional, Piazza, Francesco, additional, Pravato, Stefano, additional, Ruocco, Valeria, additional, Scapinello, Greta, additional, Vianello, Fabrizio, additional, Zambello, Renato, additional, Zatta, Ivan, additional, Zoletto, Simone, additional, Padoan, Andrea, additional, Trentin, Livio, additional, and Visentin, Andrea, additional

Published
2023
Full Text
View/download PDF

9. Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia

Author

Pizzi, Marco, primary, Vianello, Fabrizio, additional, Lorenzi, Luisa, additional, Binotto, Gianni, additional, Sbaraglia, Marta, additional, Scarmozzino, Federico, additional, De Crescenzo, Andrea, additional, Guzzardo, Vincenza, additional, Zoletto, Simone, additional, d'Amore, Fabio, additional, Friziero, Alberto, additional, D'Adda, Mariella, additional, Facchetti, Fabio, additional, and Dei Tos, Angelo Paolo, additional

Published
2023
Full Text
View/download PDF

10. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies

Author

Angotzi, Francesco, Petrella, Marco, Berno, Tamara, Binotto, Gianni, Bonetto, Giorgia, Branca, Antonio, Carraro, Marco, Cavaretta, Chiara Adele, Cellini, Alessandro, D’Amore, Fabio, Forlani, Laura, Gianesello, Ilaria, Gurrieri, Carmela, Imbergamo, Silvia, Lessi, Federica, Maroccia, Antonio, Mazzetto, Federica, Pavan, Laura, Pezone, Sara, Piazza, Francesco, Pravato, Stefano, Ruocco, Valeria, Scapinello, Greta, Vianello, Fabrizio, Zambello, Renato, Zatta, Ivan, Zoletto, Simone, Padoan, Andrea, Trentin, Livio, and Visentin, Andrea

Published
2023

12. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”

Author

Di Giusto, Sara, primary, Toffoletti, Eleonora, additional, Bonifacio, Massimiliano, additional, Binotto, Gianni, additional, Miggiano, Maria Cristina, additional, Calistri, Elisabetta, additional, Stulle, Manuela, additional, Ermacora, Anna, additional, Stella, Rossella, additional, Scaffidi, Luigi, additional, D'Amore, Fabio, additional, Scotton, Giorgia, additional, Griguolo, Davide, additional, De Matteis, Giovanna, additional, Bertorelle, Roberta, additional, Krampera, Mauro, additional, Semenzato, Gianpietro, additional, Fanin, Renato, additional, Damiani, Daniela, additional, and Tiribelli, Mario, additional

Published
2022
Full Text
View/download PDF

15. Thrombopoietin receptor agonists increase splenic regulatory T‐cell numbers in immune thrombocytopenia

Author

Pizzi, Marco, primary, Vianello, Fabrizio, additional, Binotto, Gianni, additional, Vianelli, Nicola, additional, Carli, Giuseppe, additional, Auteri, Giuseppe, additional, Nichele, Ilaria, additional, Sbaraglia, Marta, additional, Zoletto, Simone, additional, Scarmozzino, Federico, additional, Bresciani, Rita, additional, d'Amore, Fabio, additional, Friziero, Alberto, additional, Guzzardo, Vincenza, additional, Bertozzi, Irene, additional, Famengo, Barbara, additional, d'Amore, Emanuele S. G., additional, Sabattini, Elena, additional, and Dei Tos, Angelo Paolo, additional

Published
2022
Full Text
View/download PDF

16. Use of catheter-based cholangioscopy in the diagnosis of indeterminate stenosis: a multi-centre experience

Author

PALLIO, Socrate, primary, SINAGRA, Emanuele, additional, SANTAGATI, Alessio, additional, D’AMORE, Fabio, additional, POMPEI, Giancarlo, additional, CONOSCENTI, Giuseppe, additional, ROMEO, Fabio, additional, BORINA, Eleonora, additional, MELITA, Giuseppinella, additional, ROSSI, Francesca, additional, MAIDA, Marcello, additional, ALLORO, Rita, additional, TARANTINO, Ilaria, additional, and RAIMONDO, Dario, additional

Published
2022
Full Text
View/download PDF

17. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the "GRUPPO TRIVENETO LMC".

Author

Di Giusto, Sara, Toffoletti, Eleonora, Bonifacio, Massimiliano, Binotto, Gianni, Miggiano, Maria Cristina, Calistri, Elisabetta, Stulle, Manuela, Ermacora, Anna, Stella, Rossella, Scaffidi, Luigi, D'Amore, Fabio, Scotton, Giorgia, Griguolo, Davide, De Matteis, Giovanna, Bertorelle, Roberta, Krampera, Mauro, Semenzato, Gianpietro, Fanin, Renato, Damiani, Daniela, and Tiribelli, Mario

Subjects
CHRONIC myeloid leukemia, PROTEIN-tyrosine kinase inhibitors, RECEIVER operating characteristic curves
Abstract

We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G‐TKIs) while in sustained deep molecular response. Patients were divided among those who maintained response (group 1, n = 123) and those who lost major molecular response (group 2, n = 45). Mean BCR::ABL1 RNA levels 1 month after discontinuation were higher in group 2 than in group 1 (p = 0.0005) and the difference was more evident 2 months after stop (p < 0.0001). The same trend was found both for imatinib and 2G‐TKIs. A receiver operating characteristic (ROC) analysis to determine a threshold value of BCR::ABL1 at 1 month after discontinuation identified a cut‐off value of 0.0051%, with 92.2% specificity, 31.7% sensitivity and a likelihood ratio of 4.087. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Digital single‑operator cholangioscopy in treating difficult biliary stones: results from a multicenter experience

Author

PALLIO, Socrate, primary, SINAGRA, Emanuele, additional, SANTAGATI, Alessio, additional, D'AMORE, Fabio, additional, ROSSI, Francesca, additional, CONOSCENTI, Giuseppe, additional, ROMEO, Fabio, additional, BORINA, Eleonora, additional, BELLERONE, Roberta, additional, MAIDA, Marcello, additional, ALLORO, Rita, additional, TARANTINO, Ilaria, additional, and RAIMONDO, Dario, additional

Published
2021
Full Text
View/download PDF

19. EFFECTIVENESS OF 1-L POLYETHYLENE GLYCOL PLUS ASCORBATE VERSUS 4-L POLYETHYLENE GLYCOL FOR COLONOSCOPY CLEANSING IN SPLIT-DOSE: A MULTICENTRE, RANDOMIZED, CLINICAL TRIAL (OVER2019)

Author

Vassallo, Roberto, Maida, Marcello, Zullo, Angelo, Venezia, Ludovica, Montalbano, Luigi maria, Di Mitri, Roberto, Peralta, Marco, Virgilio, Clara, Pallio, Socrate, Pluchino, Dario, D'Amore, Fabio, Santagati, Alessio, Sinagra, Emanuele, Graceffa, Pietro, Nicosia, Giuseppe, Camilleri, Salvatore, Gibiliaro, Gerlando, Hadi, Yasmin Abdel, Gabriele, Rancatore, Scalisi, Giuseppe, Melita, Giuseppinella, Magnano, Antonio, and Conoscenti, Giuseppe

Published
2023
Full Text
View/download PDF

20. Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications

Author

Pizzi, Marco, primary, Friziero, Alberto, additional, Vianello, Fabrizio, additional, Binotto, Gianni, additional, Da Dalt, Gianfranco, additional, Zoletto, Simone, additional, Carraro, Elisa, additional, Fassan, Matteo, additional, Sbaraglia, Marta, additional, Sperti, Cosimo, additional, Baldan, Nicola, additional, D’Amore, Fabio, additional, Bertozzi, Irene, additional, Righi, Simona, additional, Pierobon, Elisa Sefora, additional, Moletta, Lucia, additional, Capovilla, Giovanni, additional, Grego, Andrea, additional, Sabattini, Elena, additional, Fabris, Fabrizio, additional, Merigliano, Stefano, additional, and Dei Tos, Angelo Paolo, additional

Published
2020
Full Text
View/download PDF

21. Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Author

Polverelli, Nicola, primary, Elli, Elena M., additional, Abruzzese, Elisabetta, additional, Palumbo, Giuseppe A., additional, Benevolo, Giulia, additional, Tiribelli, Mario, additional, Bonifacio, Massimiliano, additional, Tieghi, Alessia, additional, Caocci, Giovanni, additional, D'Adda, Mariella, additional, Bergamaschi, Micaela, additional, Binotto, Gianni, additional, Heidel, Florian H., additional, Cavazzini, Francesco, additional, Crugnola, Monica, additional, Pugliese, Novella, additional, Bosi, Costanza, additional, Isidori, Alessandro, additional, Bartoletti, Daniela, additional, Auteri, Giuseppe, additional, Latagliata, Roberto, additional, Gandolfi, Lisa, additional, Martino, Bruno, additional, Scaffidi, Luigi, additional, Cattaneo, Daniele, additional, D’Amore, Fabio, additional, Trawinska, Malgorzata M., additional, Stella, Rossella, additional, Markovic, Uros, additional, Catani, Lucia, additional, Pane, Fabrizio, additional, Cuneo, Antonio, additional, Krampera, Mauro, additional, Semenzato, Gianpietro, additional, Lemoli, Roberto M., additional, Vianelli, Nicola, additional, Breccia, Massimo, additional, Russo, Domenico, additional, Cavo, Michele, additional, Iurlo, Alessandra, additional, and Palandri, Francesca, additional

Published
2020
Full Text
View/download PDF

22. Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival

Author

Palandri, Francesca, primary, Bartoletti, Daniela, additional, Benevolo, Giulia, additional, Breccia, Massimo, additional, Elli, Elena M, additional, Cavazzini, Francesco, additional, Binotto, Gianni, additional, Tieghi, Alessia, additional, Tiribelli, Mario, additional, Heidel, Florian H., additional, Bonifacio, Massimiliano, additional, Pugliese, Novella, additional, Caocci, Giovanni, additional, Crugnola, Monica, additional, Mendicino, Francesco, additional, Martino, Enrica A, additional, D'Addio, Alessandra, additional, Tomassetti, Simona, additional, Martino, Bruno, additional, Auteri, Giuseppe, additional, Catani, Lucia, additional, Stella, Rossella, additional, D'Amore, Fabio, additional, Scaffidi, Luigi, additional, Polverelli, Nicola, additional, Pane, Fabrizio, additional, Cuneo, Antonio, additional, Krampera, Mauro, additional, Semenzato, Gianpietro, additional, Lemoli, Roberto M., additional, Vianelli, Nicola, additional, Cavo, Michele, additional, Palumbo, Giuseppe A., additional, and Latagliata, Roberto, additional

Published
2020
Full Text
View/download PDF

23. First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria

Author

Latagliata, Roberto, primary, Breccia, Massimo, additional, Di Veroli, Ambra, additional, Benevolo, Giulia, additional, Elli, Elena M, additional, Cavazzini, Francesco, additional, Binotto, Gianni, additional, Tieghi, Alessia, additional, Tiribelli, Mario, additional, Heidel, Florian H., additional, Bonifacio, Massimiliano, additional, Pugliese, Novella, additional, Caocci, Giovanni, additional, Crugnola, Monica, additional, Mendicino, Francesco, additional, Martino, Enrica Antonia, additional, D'Addio, Alessandra, additional, Tomassetti, Simona, additional, Martino, Bruno, additional, Bartoletti, Daniela, additional, Auteri, Giuseppe, additional, Catani, Lucia, additional, Stella, Rossella, additional, D'Amore, Fabio, additional, Scaffidi, Luigi, additional, Polverelli, Nicola, additional, Pane, Fabrizio, additional, Cuneo, Antonio, additional, Krampera, Mauro, additional, Semenzato, Gianpietro, additional, Lemoli, Roberto Massimo, additional, Vianelli, Nicola, additional, Cavo, Michele, additional, Palumbo, Giuseppe A., additional, and Palandri, Francesca, additional

Published
2020
Full Text
View/download PDF

24. BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC"

Author

Di Giusto, Sara, primary, Toffoletti, Eleonora, additional, Bonifacio, Massimiliano, additional, Binotto, Gianni, additional, Miggiano, Maria Cristina, additional, Calistri, Elisabetta, additional, Stulle, Manuela, additional, Ermacora, Anna, additional, Stella, Rossella, additional, Scaffidi, Luigi, additional, D'Amore, Fabio, additional, Scotton, Giorgia, additional, De Matteis, Giovanna, additional, Bertorelle, Roberta, additional, Fanin, Renato, additional, Krampera, Mauro, additional, Semenzato, Gianpietro, additional, Damiani, Daniela, additional, and Tiribelli, Mario, additional

Published
2020
Full Text
View/download PDF

25. Histology of the spleen in immune thrombocytopenia: clinical‐pathological characterization and prognostic implications.

Author

Pizzi, Marco, Friziero, Alberto, Vianello, Fabrizio, Binotto, Gianni, Da Dalt, Gianfranco, Zoletto, Simone, Carraro, Elisa, Fassan, Matteo, Sbaraglia, Marta, Sperti, Cosimo, Baldan, Nicola, D'Amore, Fabio, Bertozzi, Irene, Righi, Simona, Pierobon, Elisa Sefora, Moletta, Lucia, Capovilla, Giovanni, Grego, Andrea, Sabattini, Elena, and Fabris, Fabrizio

Subjects
IDIOPATHIC thrombocytopenic purpura, T helper cells, CYTOTOXIC T cells, SPLEEN, HISTOLOGY
Abstract

Objective: Immune thrombocytopenia (ITP) is an acquired disorder, characterized by immune‐mediated platelet destruction. The spleen plays a key pathogenic role in ITP and splenectomy is a valuable second‐line therapy for this disease. Little is known on ITP spleen histology and response to splenectomy is unpredictable. This study aims to characterize ITP spleen histology and assess possible predictors of splenectomy outcome. Methods: A series of 23 ITP spleens were retrospectively assessed for the following histological parameters: density of lymphoid follicles (LFs), marginal zones (MZs), T helper and cytotoxic T cells; presence of reactive germinal centers (GCs); width of perivascular T cell sheaths; and red pulp features. Clinical and histological data were matched with postsplenectomy platelet counts to assess their prognostic relevance. Results: Three histological patterns were documented: a hyperplastic white pulp pattern, a non‐activated white pulp pattern (lacking GCs), and a white pulp‐depleted pattern. Poor surgical responses were associated with presplenectomy high‐dose steroid administration, autoimmune comorbidities and low T follicular helper cell density. The combination of such parameters stratified patients into different splenectomy response groups. The removal of accessory spleens was also associated with better outcome. Conclusion: ITP spleens are histologically heterogeneous and clinical‐pathological parameters may help predict the splenectomy outcome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis

Author

F. De Martino, Bruno Trimarco, Caterina Marciano, Fabio Marsico, Lars H. Lund, Gianluigi Savarese, Carmen D'Amore, Santo Dellegrottaglie, Pasquale Perrone-Filardi, Paola Gargiulo, Gargiulo, P., Savarese, G., D'Amore, Fabio, De Martino, Federica, Lund, L. H., Marsico, F., Dellegrottaglie, S., Marciano, C., Trimarco, B., and Perrone-Filardi, P.

Subjects
Diabetes mellitu, medicine.medical_specialty, Glucagon-like peptide-1 agonist, Diabetic Angiopathie, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), Cardiovascular event, 030204 cardiovascular system & hematology, Placebo, Incretins, Risk Assessment, Nephropathy, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Glucagon-Like Peptide 1, Risk Factors, law, Internal medicine, Diabetes mellitus, Nutrition and Dietetic, medicine, Humans, Hypoglycemic Agents, 030212 general & internal medicine, Retinopathy, Stroke, Nutrition and Dietetics, Hypoglycemic Agent, business.industry, Risk Factor, Type 2 Diabetes Mellitus, Diabetic retinopathy, Incretin, medicine.disease, Treatment Outcome, Endocrinology, Diabetes Mellitus, Type 2, Meta-analysis, Macrovascular event, Cardiology and Cardiovascular Medicine, business, Microvascular event, Diabetic Angiopathies, Human, Signal Transduction
Abstract

Aims Glucagon-like peptide-1 (GLP-1) agonists improve glycaemic control in type 2 diabetes mellitus (DM). Outcome trials investigating macro and microvascular effects of GLP-1 agonists reported conflicting results. The aim of this study was to assess, in a meta-analysis, the effects of GLP-1 agonists on mortality, major nonfatal cardiovascular (CV) events, renal and retinal events. Data synthesis MEDLINE, Cochrane, ISI Web of Science, SCOPUS and ClinicalTrial.gov databases were searched for articles published until June 2017. Randomized trials enrolling more than 200 patients, comparing GLP-1 versus placebo or active treatments in patients with DM, and assessing outcomes among all-cause death, CV death, MI, stroke, HF, diabetic retinopathy and nephropathy were included. 77 randomized trials enrolling 60,434 patients were included. Compared to control, treatment with GLP-1 significantly reduced the risk of all-cause death (RR: 0.888; CI: 0.804–0.979; p = 0.018) and the risk of CV death (RR: 0.858; CI: 0.757–0.973; p = 0.017). GLP-1 agonists did not affect the risk of MI (RR: 0.917; CI: 0.830–1.014; p = 0.092) as well as the risk of stroke (RR: 0.882; CI: 0.759–1.023; p = 0.097), HF (RR: 0.967; CI: 0.803–1.165; p = 0.725), retinopathy (RR: 1.000; CI: 0.807–1.238; p = 0.997) and nephropathy (RR: 0.866; CI: 0.625–1.199; p = 0.385). Conclusions Treatment with GLP-1 agonists in DM patients is associated with a significant reduction of all cause and CV mortality.

Published
2017
Full Text
View/download PDF

28. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.

Author

Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, and Palandri F

Subjects
Adult, Aged, Aged, 80 and over, Arteries pathology, Case-Control Studies, Female, Follow-Up Studies, Humans, Incidence, Janus Kinase Inhibitors administration & dosage, Janus Kinase Inhibitors therapeutic use, Janus Kinase Inhibitors toxicity, Lymphoma diagnosis, Lymphoma epidemiology, Male, Middle Aged, Multivariate Analysis, Neoplasms, Second Primary epidemiology, Neoplasms, Second Primary pathology, Nitriles, Primary Myelofibrosis pathology, Pyrazoles administration & dosage, Pyrazoles therapeutic use, Pyrazoles toxicity, Pyrimidines, Retrospective Studies, Risk Factors, Skin Neoplasms diagnosis, Skin Neoplasms epidemiology, Thrombocytosis chemically induced, Thrombocytosis diagnosis, Thrombosis chemically induced, Thrombosis diagnosis, Janus Kinase Inhibitors adverse effects, Neoplasms, Second Primary chemically induced, Primary Myelofibrosis drug therapy, Pyrazoles adverse effects
Abstract

Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs). We analyzed the incidence, risk factors and outcome of SPMs in 700 MF patients treated with RUX in a real-world context. Median follow-up from starting RUX was 2·9 years. Overall, 80 (11·4%) patients developed 87 SPMs after RUX start. NMSCs were the most common SPMs (50·6% of the cases). Multivariate analysis demonstrated that male sex [hazard ratio (HR): 2·37, 95% confidence interval (95%CI): 1·22-4·60, P = 0·01] and thrombocytosis> 400 × 10 9 /l at RUX start (HR:1·98, 95%CI: 1·10-4·60, P = 0·02) were associated with increased risk for SPMs. Risk factors for NMSC alone were male sex (HR: 3·14, 95%CI: 1·24-7·92, P = 0·02) and duration of hydroxycarbamide and RUX therapy > 5 years (HR: 3·20, 95%CI: 1·17-8·75, P = 0·02 and HR: 2·93, 95%CI: 1·39-6·17, P = 0·005 respectively). In SPMs excluding NMSCs, male sex (HR: 2·41, 95%CI: 1·11-5·25, P = 0·03), platelet > 400 × 10 9 /l (HR: 3·30, 95%CI: 1·67-6·50, P = 0·001) and previous arterial thromboses (HR: 3·47, 95%CI: 1·48-8·14, P = 0·004) were shown to be associated with higher risk of SPMs. While it is reassuring that no aggressive lymphoma was documented, active skin surveillance is recommended in all patients and particularly after prolonged hydroxycaramide therapy; oncological screening should be triggered by thrombocytosis and arterial thrombosis, particularly in males., (© 2020 British Society for Haematology and John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results